AI radiology software that clears Europe’s CE mark first waits a median 17.5 months for FDA clearance, while FDA-first devices get European authorization in just 3.5 months, according to a new npj Digital Medicine analysis.
The researchers reviewed 239 AI-enabled radiology devices using Europe’s Health AI Register and FDA sources. Of those, 128 carried only a CE mark, 95 gained CE marking before FDA clearance, and 16 went the opposite direction.
The gap matters for patients and vendors alike. Radiograph interpretation software faced the longest delays to second authorization, while devices classified EU Class IIa moved faster. Devices backed by peer-reviewed evidence also trended toward shorter intervals, though the effect did not reach statistical significance.
The pattern reflects structural differences in the two regulatory systems. Europe’s framework leans on notified bodies and lower-risk classifications, while the FDA requires a dedicated 510(k) or De Novo pathway for most AI software. Companies often enter Europe first precisely because it is faster, then pay the price later when US clearance takes longer than planned.
The authors call the asymmetry persistent and say it should inform global regulatory strategy. For radiology AI vendors, the study is a practical roadmap: expect a longer second-act wait if you launch in Europe, and plan US submission timing accordingly.
